Phase III trial of Ninlaro as first-line maintenance therapy meets PFS in multiple myeloma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The phase III Takeda TOURMALINE-MM4 study met its primary endpoint of progression-free survival in multiple myeloma not treated with stem cell transplantation.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login